Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Antibodies Protect Against Range of Flu Viruses

Published: Wednesday, August 29, 2012
Last Updated: Wednesday, August 29, 2012
Bookmark and Share
A research team find antibodies that neutralize a broad range of influenza B viruses.

Scientists have isolated antibodies that protect mice against a variety of lethal influenza B viruses. One of them also guards against influenza A viruses.

The accomplishment points the way toward universal approaches to combat all influenza A and B viruses.

The flu is a contagious respiratory illness caused by influenza viruses that infect the nose, throat and lungs. They can cause mild to severe illness, and sometimes death. Influenza viruses continuously change, or mutate.

Vaccines need to be reformulated each year to match new circulating strains.

A universal influenza vaccine-one effective against multiple strains for several years-would have an enormous impact on public health.

Influenza viruses are classified as types A, B and C. Type A viruses include the H5N1 avian virus, the 1918 pandemic flu virus and the seasonal H1N1 flu.

Type A has several subtypes, but researchers recently isolated antibodies that neutralize a broad range of influenza A viruses. These attach to a region on the stem of hemagglutinin (HA), a protein on the virus surface that allows it to enter and spread between cells.

Unlike HA's head, which mutates quickly, the stem varies relatively little from strain to strain.

Influenza B viruses have received less attention than type A viruses. Type B viruses aren't harbored by large numbers of animals, a requirement for creating pandemics.

Nevertheless, a significant number of seasonal flu cases are caused by influenza B. Two distinct lineages of influenza B-the Victoria and Yamagata lineages-are in circulation.

A research team led by Dr. Ian A. Wilson at the Scripps Research Institute and Drs. Jaap Goudsmit and Robert Friesen of the Crucell Vaccine Institute in the Netherlands set out to find antibodies that neutralize a broad range of influenza B viruses.

The scientists took a similar approach to the one that helped them find broadly neutralizing antibodies to influenza A. They screened antibodies from people who were recently vaccinated with the seasonal influenza vaccine, searching for the ability to bind HAs of both influenza B lineages.

Their work was funded in part by NIH’s National Institute of General Medical Sciences (NIGMS) and National Center for Research Resources (NCRR).

In the online edition of Science on August 9, 2012, the researchers described 3 antibodies (called CR8033, CR8071 and CR9114) that bound HA from both influenza B lineages.

One, CR9114, also bound influenza A viruses. Structural studies revealed that CR8033 and CR8071 bind parts of the HA head region, whereas CR9114 binds a part of the HA stem.

All 3 antibodies protected mice from lethal influenza B viruses of both lineages. Significantly, CR9114 also protected against lethal doses of influenza A H1N1 and H3N2 viruses.

Vaccines that induce the body to make antibodies against the region that CR9114 binds might one day provide protection against all influenza A and influenza B viruses.

“To develop a truly universal flu vaccine or therapy, one needs to be able to provide protection against influenza A and influenza B viruses, and with this report we now have broadly neutralizing antibodies against both,” Wilson says.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

In Uveitis, Bacteria in Gut May Instruct Immune Cells to Attack the Eye
NIH scientists propose novel mechanism to explain autoimmune uveitis.
Wednesday, August 19, 2015
Novel Mechanism to Explain Autoimmune Uveitis Proposed
A new study on mice suggests that bacteria in the gut may provide a kind of training ground for immune cells to attack the eye.
Wednesday, August 19, 2015
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Tuesday, July 21, 2015
Starting Antiretroviral Treatment Early Improves Outcomes for HIV-infected Individuals
NIH-funded trial results likely will impact global treatment guidelines.
Thursday, May 28, 2015
For Most Children with HIV and Low Immune Cell Count, Cells Rebound After Treatment
NIH-funded study finds T-cell level returns to normal with time.
Saturday, March 28, 2015
Strengthening the Immune System’s Fight Against Brain Cancer
NIH-funded research suggests novel way to improve vaccine efficacy in brain tumors.
Friday, March 20, 2015
Autoimmune Disease Super-Regulators Uncovered
Scientists discovered key genetic switches, called super-enhancers, involved in regulating the human immune system.
Tuesday, March 17, 2015
NIH Announces $41.5 Million in Funding for the Human Placenta Project
Better understanding of the placenta promises to improve the health of mothers and children.
Tuesday, March 03, 2015
NIH-funded Scientists Create Potential Long-acting HIV Therapeutic
New molecule also might prevent HIV infection.
Tuesday, February 24, 2015
Link Between Powerful Gene Regulatory Elements and Autoimmune Diseases Revealed
Findings point to potential drug targets.
Thursday, February 19, 2015
NIH-Sponsored HIV Vaccine Trial Launches In South Africa
Early-stage trial aims to build on RV144 results.
Thursday, February 19, 2015
Stem Cell Transplants May Halt Progression of Multiple Sclerosis
NIH-funded study yields encouraging early results.
Tuesday, December 30, 2014
Candidate H7N9 Avian Flu Vaccine Works Better With Adjuvant
Results of large NIH-sponsored trial demonstrate improved vaccine response when an adjuvant was used.
Wednesday, October 08, 2014
NIH Awards Seven New Vaccine Adjuvant Discovery Contracts
Total funding for these contracts reach approximately $70 million over five years.
Tuesday, October 07, 2014
NIH to Admit Patient Exposed to Ebola Virus for Observation
Ebola patients can be safely cared for at any hospital that follows CDC's infection control recommendations.
Wednesday, October 01, 2014
Scientific News
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
Research Finding Could Lead to Targeted Therapies for IBD
Findings published online in Cell Reports.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos